Advertisement

Pharmacy World & Science

, Volume 30, Issue 1, pp 128–135 | Cite as

Description of pharmacist interventions during physician–pharmacist co-management of hypertension

  • Shannon J. Von Muenster
  • Barry L. CarterEmail author
  • Cynthia A. Weber
  • Michael E. Ernst
  • Jessica L. Milchak
  • Jennifer J. G. Steffensmeier
  • Yinghui Xu
Research Article

Abstract

Objective The aim of this study is to describe recommendations made by clinical pharmacists when co-managing hypertension with physicians. Setting Two family medicine clinics at a major teaching hospital in the mid-western United States. Method This report details the specific recommendations made by pharmacists during a prospective randomized controlled clinical trial. Patients with uncontrolled hypertension were enrolled in a 9-month intensive pharmacist–physician co-management study. Clinical pharmacists saw patients at baseline, 2, 4, 6, and 8 month visits. Optional visits were allowed between required visits. Main outcome measure For this analysis, pharmacist recommendations were grouped. Physician acceptance of the pharmacists’ recommendations was also evaluated. Results Data from 101 patients were included and analyzed in this study. Changes in drug therapy were recommended 267 times for these 101 patients. Most recommendations for a change in treatment involved adding a new antihypertensive medication (46.4%) or increasing a dose (33.3%). The majority of pharmacist recommendations to modify drug therapy were made at the baseline visit (41.6%), with 76.8% of recommendations made by the 2 month visit. Physicians accepted and implemented 95.9% of the 267 pharmacist recommendations to modify drug therapy. Pharmacists recommended no change in the treatment plan 361 times, most often because the patient’s blood pressure (BP) had achieved the goal. Average BP decreased from 153.1 ± 10.0/84.9 ± 12.0 mmHg (average ± SD) at baseline to 124.2 ± 9.7/74.7 ± 9.6 mmHg (P < 0.001) at the end of 9 months, with 89.1% (P < 0.001) of patients reaching their BP goal. Conclusion Pharmacist recommendations for alterations in drug therapy generally occurred early in the course of the study and were largely to intensify therapy through higher dosages or additional medications. Pharmacist–physician co-management of BP is effective at reducing BP and improving BP control rates.

Keywords

Ambulatory care facilities Cardiovascular outcomes Clinical pharmacy Hypertension Interventions Pharmacist USA 

Notes

Acknowledgements

The authors would like to acknowledge the assistance of Janyce Stewart, RN and Gail Ardery, PhD (project managers); George Bergus, MD, Jeffrey Dawson, ScD, Karen Farris, PhD, William Doucette, PhD, Elizabeth Chrischilles, PhD, and Arthur Hartz, MD, PhD, (study steering committee); Karen Kluesner, RN and Sheryl Eastin, RN (research nurses); Paul James, MD, Christopher Goerdt, MD, and David Katz, MD (data and safety monitoring board).

Funding

This project was supported by the National Heart, Lung, and Blood Institute, 1 R01 HL069801-01A1. Dr. Carter is also supported by the CRIISP Center, Iowa City Department of Veterans Affairs.

Conflicts of Interest

Dr. Carter is also supported by the Center for Research in Implementation in Innovative Strategies in Practice (CRIISP), Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HFP 04-149). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. Dr. Carter receives funding from NHLBI for another study and he is a paid investigator/educator for the dissemination program: “A Joint Project of the National High Blood Pressure Education Program and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.” The other authors have no conflicts of interest.

References

  1. 1.
    2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011–53.Google Scholar
  2. 2.
    World Health Report 2002. Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002. http://www.who.int/whr/2002/.
  3. 3.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42(6):1206–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Petrella RJ, Campbell NR. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol 2005;21(7):589–93.PubMedGoogle Scholar
  5. 5.
    CHD 2006. Blood pressure. Chapter 9, BHF Coronary heart disease statistics. Published May 2006. http://www.heartstats.org/temp/Chaptersp9.pdf.
  6. 6.
    Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49(1):69–75.PubMedCrossRefGoogle Scholar
  7. 7.
    Coca A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillen F, et al. Strategies for effective control of arterial hypertension in Spain. Consensus document. Rev Clin Esp 2006;206(10):510–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001;37(1):12–8.PubMedGoogle Scholar
  9. 9.
    Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med 1984;144(6):1159–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, et al. Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2001;37(1):19–27.PubMedGoogle Scholar
  12. 12.
    Carter BL, Zillich AJ, Elliott WJ. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens 2003;5(1):31–7.CrossRefGoogle Scholar
  13. 13.
    Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95(4):1085–90.PubMedGoogle Scholar
  14. 14.
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345(7):479–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339(27):1957–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162(4):413–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapy. Arch Intern Med 1981;141(11):1441–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med 1998;13(11):740–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Archi J, et al. Physician–pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003;23(2):209–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Erickson SR, Slaughter R, Halapy H. Pharmacists’ ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17(1):140–7.PubMedGoogle Scholar
  21. 21.
    Forstrom MJ, Ried LD, Stergachis AS, Corliss DA. Effect of a clinical pharmacist program on the cost of hypertension treatment in an HMO family practice clinic. DICP 1990;24(3):304–9.PubMedGoogle Scholar
  22. 22.
    Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36(10):1321–5.PubMedGoogle Scholar
  23. 23.
    Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006.Google Scholar
  24. 24.
    McGhan WF, Stimmel GL, Hall TG, Gilman TM. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care 1983;21(4):435–44.PubMedCrossRefGoogle Scholar
  25. 25.
    McKenney JM. Pharmacy management of hypertensive patients. J Am Pharm Assoc 1974;14(4):190–5.PubMedGoogle Scholar
  26. 26.
    McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation 1973;48(5):1104–11.PubMedGoogle Scholar
  27. 27.
    Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000;20(11):1384–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain (pharmacy) setting. J Am Pharm Assoc 1996;NS36(7):443–51.Google Scholar
  29. 29.
    Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy 2002;22(12):1533–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care 2006;44(7):646–57.PubMedCrossRefGoogle Scholar
  31. 31.
    Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med 2005;20(12):1091–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17(6):1274–85.PubMedGoogle Scholar
  33. 33.
    Carter BL, Helling DK. Ambulatory care pharmacy services: has the agenda changed? Ann Pharmacother 2000;34(6):772–87.PubMedCrossRefGoogle Scholar
  34. 34.
    Brown DJ, Helling DK, Jones ME. Evaluation of clinical pharmacist consultations in a family practice office. Am J Hosp Pharm 1979;36(7):912–5.PubMedGoogle Scholar
  35. 35.
    Chrischilles EA, Carter BL, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker MD, et al. Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc (Wash DC) 2004;44(3):337–49.Google Scholar
  36. 36.
    Haxby DG, Weart CW, Goodman BW Jr. Family practice physicians’ perceptions of the usefulness of drug therapy recommendations from clinical pharmacists. Am J Hosp Pharm 1988;45(4):824–7.PubMedGoogle Scholar
  37. 37.
    Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, et al. A cluster-randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Submitted June 2007).Google Scholar
  38. 38.
    Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421–31.PubMedCrossRefGoogle Scholar
  39. 39.
    Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;2005(45):142–61.Google Scholar
  40. 40.
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Shannon J. Von Muenster
    • 1
  • Barry L. Carter
    • 1
    • 2
    Email author
  • Cynthia A. Weber
    • 1
  • Michael E. Ernst
    • 1
    • 2
  • Jessica L. Milchak
    • 3
  • Jennifer J. G. Steffensmeier
    • 1
    • 4
  • Yinghui Xu
    • 2
  1. 1.Division of Clinical and Administrative Pharmacy, Room 527, College of PharmacyUniversity of IowaIowa CityUSA
  2. 2.Department of Family MedicineUniversity of IowaIowa CityUSA
  3. 3.Clinical Pharmacy PracticeKaiser PermanenteDenverUSA
  4. 4.Pharmacy DepartmentIowa City Veterans Affairs Medical CenterIowa CityUSA

Personalised recommendations